Literature DB >> 14703703

Detailed criteria for the assessment of clinical symptoms in a new murine model of severe allergic conjunctivitis.

Takao Nakamura1, Masako Toda, Masaharu Ohbayashi, Santa Jeremy Ono.   

Abstract

PURPOSE: The aims of this research were to: (1) generate a rapid protocol for the sensitization of rodents to a defined allergen without footpad injections yet leading to both acute- and late-phase hypersensitivity reactions in the ocular surface; and (2) define detailed criteria for the assessment of clinical symptoms in the acute-phase response.
METHODS: With the approved methods for the use of experimental animals in research and existing sensitization protocols as a starting point, we developed and tested a new protocol with respect to its ability to generate an acute- and late-phase response on ocular challenge. Clinical symptoms were assessed by a trained ophthalmologist under masked conditions, and late-phase responses determined by histologic analysis of conjunctival tissue sections.
RESULTS: A new protocol for the rapid sensitization of mice, avoiding footpad injections, yet yielding both acute- and late-phase allergic responses, was developed. Detailed criteria for the assessment of disease severity were established and tested.
CONCLUSION: This protocol establishes a murine model of allergic conjunctivitis that will be useful for both the study of the molecular and cellular basis of allergic reactions in the ocular surface and the testing of new therapies for this disease.

Entities:  

Mesh:

Year:  2003        PMID: 14703703     DOI: 10.1097/00003226-200310001-00003

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  5 in total

Review 1.  Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis.

Authors:  Gyan P Mishra; Viral Tamboli; Jwala Jwala; Ashim K Mitra
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2011-01

2.  Aggravation of conjunctival early-phase reaction by Staphylococcus enterotoxin B via augmentation of IgE production.

Authors:  Dai Miyazaki; Waka Ishida; Takeshi Tominaga; Tamaki Sumi; Atsuki Fukushima
Journal:  Jpn J Ophthalmol       Date:  2010-11-05       Impact factor: 2.447

3.  Macrophage inflammatory protein-1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions.

Authors:  Dai Miyazaki; Takao Nakamura; Masako Toda; Kam-Wa Cheung-Chau; Ricardo M Richardson; Santa Jeremy Ono
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

4.  Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/CCR3 blockade.

Authors:  Dai Miyazaki; Takao Nakamura; Masaharu Ohbayashi; Chuan Hui Kuo; Naoki Komatsu; Keiko Yakura; Takeshi Tominaga; Yoshitsugu Inoue; Hidemitsu Higashi; Meguru Murata; Shuzo Takeda; Atsuki Fukushima; Fu-Tong Liu; Marc E Rothenberg; Santa Jeremy Ono
Journal:  Int Immunol       Date:  2009-01-15       Impact factor: 4.823

5.  A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva.

Authors:  Takao Nakamura; Masaharu Ohbayashi; Masako Toda; David A Hall; Carmel M Horgan; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.